Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of **azithromycin**, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and **colchicine**, a microtubule inhibitor used primarily in the management of gout and familial Mediterranean fever. This combination is not marketed as a fixed co-formulated product, but both drugs may be administered concurrently in clinical settings. Colchicine acts by inhibiting microtubule polymerization, leading to disruption of neutrophil activity and reductions in inflammation. Azithromycin is primarily bacteriostatic, though it may exhibit bactericidal activity at high concentrations or against certain organisms. These drugs have overlapping metabolic pathways involving P-glycoprotein; however, available studies indicate that, unlike clarithromycin, azithromycin does not significantly increase colchicine exposure, and dose adjustment is generally not required when used together in patients with normal renal and hepatic function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + colchicine.